We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Votes to Approve Arranon, Revlimid
FDA Panel Votes to Approve Arranon, Revlimid
September 16, 2005
FDA cancer drug experts have endorsed two experimental cancer treatments — GlaxoSmithKline’s (GSK’s) leukemia and lymphoma drug Arranon and Celegene’s malignant blood cell-disorder drug Revlimid.